Supernus Pharmaceuticals develops and commercializes treatments for central nervous system diseases. Company news centers on its neuroscience portfolio, including approved treatments for attention-deficit hyperactivity disorder, Parkinson's disease-related dyskinesia and hypomobility, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
Recurring updates cover product revenue trends for Qelbree, GOCOVRI, ZURZUVAE, ONAPGO and other CNS therapies, quarterly financial results, collaboration and licensing revenue, investor conference participation, and pipeline activity for novel CNS product candidates such as SPN-820 in major depressive disorder.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that its CEO, Jack Khattar, will present a company overview and update at two upcoming November conferences. The Stifel 2022 Healthcare Conference is scheduled for November 15, 2022, at 8:00 a.m. ET in New York. The 13th Annual Jefferies London Healthcare Conference will take place on November 17, 2022, at 9:05 a.m. ET / 2:05 p.m. GMT in London. Interested investors can arrange meetings through conference coordinators and access live webcasts on the Company's website.
Supernus Pharmaceuticals reported total revenues of $177.4 million for Q3 2022, a 19% increase year-over-year. The company raised its full-year guidance for operating earnings to $35 million to $45 million and total revenues to $650 million to $680 million. Qelbree prescriptions rose to 94,328, a 50% increase from Q2 2022, with net product sales of $18.3 million. GOCOVRI's sales reached $27.9 million, up 16% from the previous year. Adjusted operating earnings for Q3 were $25.4 million, down from $43.3 million in 2021.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced its upcoming third quarter 2022 financial results, set to be reported after market close on November 8, 2022. CEO Jack Khattar and CFO Tim Dec will host a conference call to discuss the results at 4:30 p.m. ET on the same day.
The call will be available via live webcast on the company's Investor Relations website, where a replay will also be accessible for 60 days following the event.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that the FDA issued a Complete Response Letter (CRL) for its SPN-830 New Drug Application (NDA). This investigational apomorphine infusion device targets motor fluctuations in Parkinson's disease. The CRL requests further information about labeling, product quality, and device performance. Notably, the FDA's initial findings do not ask for additional efficacy and safety studies. Supernus aims to address the FDA's concerns and expedite the NDA resubmission, which will undergo a six-month review timeline.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that President and CEO Jack Khattar will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference on September 7, 2022, at 8:35 a.m. ET. The conference runs from September 7-9, 2022, at Encore Boston Harbor, Massachusetts. Investors can access a live audio webcast of the presentation via the Company’s website, with an archived replay available for 60 days. Supernus focuses on developing treatments for central nervous system diseases.
Supernus Pharmaceuticals reported Q2 2022 revenues of $170.1 million, reflecting a 20% increase year-over-year. The company's GAAP operating earnings stood at $11.3 million, down from $34.1 million in Q2 2021. Notably, Qelbree prescriptions surged to 62,938, marking a 33% increase from Q1 2022. Net product sales for Qelbree grew by 34% quarter-over-quarter, reaching $11.1 million. The company maintains a robust cash position of $508.2 million.
Supernus Pharmaceuticals (Nasdaq: SUPN) has announced the upcoming release of its financial and business results for Q2 2022 on August 4, 2022, after market close. The conference call, hosted by President and CEO Jack Khattar and CFO Tim Dec, will begin at 4:30 p.m. ET. Investors can pre-register for the call and access a live webcast through the company's Investor Relations website. Supernus is focused on CNS disease treatments and is advancing a range of product candidates for various neurological disorders.
Supernus Pharmaceuticals (Nasdaq: SUPN) will present at the Jefferies Healthcare Conference on June 9, 2022, at 10:30 a.m. ET. CEO Jack Khattar will lead the presentation, highlighting the company’s focus on CNS diseases.
Investors can arrange meetings through the conference coordinator. The event occurs from June 8-10, 2022, at the New York Marriott Marquis. A live audio webcast will be available on the company's website, with a replay for 60 days post-conference. Supernus is known for its CNS product portfolio, including treatments for epilepsy, migraines, and Parkinson’s disease.
Supernus Pharmaceuticals reported first quarter 2022 revenues of $152.5 million, a 16% increase year-over-year. Net earnings rose to $25.6 million or $0.43 per diluted share. GAAP operating income stood at $2.0 million, while non-GAAP operating income was $28.0 million, reflecting an 11% increase from 2021. The FDA approved Qelbree® for adult ADHD treatment, contributing to 47,324 prescriptions in Q1, a 38% increase from Q4 2021. Financial guidance for 2022 remains $640 - $680 million in total revenues.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced it will report Q1 2022 financial results after the market closes on May 9, 2022. President and CEO Jack Khattar and CFO Tim Dec will host a conference call at 4:30 p.m. ET to discuss the results, with a Q&A session following. A live webcast will be available on the Supernus website. The company specializes in developing CNS disease treatments, including products for epilepsy, migraine, and Parkinson’s disease.